CTOs on the Move

SeLux Diagnostics

www.seluxdx.com

 
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.seluxdx.com
  • 56 Roland Street Suite 206
    Charlestown, MA USA 02129
  • Phone: 617.945.9383

Executives

Name Title Contact Details

Funding

SeLux Diagnostics raised $25M on 12/12/2018
SeLux Diagnostics raised $14.6M on 06/08/2021

Similar Companies

GentiBio

GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.

Alta Biomedical Group

Alta Biomedical Group is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Liquidia Technologies

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.

M2Gen

M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company`s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. M2GEN`s Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to the fight against cancer for patients today and tomorrow. M2GEN currently has more than 300,000 total consented patients across a network of 18 cancer centers in 10 states.

Aditx Therapeutics

Prolonging Life and Enhancing its Quality Technology to improve the health of your immune system Learn more about our technology AditxtScore™ AditxtReprogramming™ AditxtScore™